local_hospital

Nemocnice Rudolfa a Stefanie Benešov, a. s.

Address
Machova 400, 256 01 Benesov, Czechia

Nemocnice Rudolfa a Stefanie Benešov, a. s.

Nemocnice Rudolfa a Stefanie Benešov is a medical research institution actively engaged in critical care and infectious disease research. The center demonstrates particular expertise in evaluating novel therapeutic interventions for patients with severe viral lung infections requiring advanced respiratory support.

  • Severe viral lung infections requiring supplemental oxygen therapy
  • Novel biologic therapies for critically ill patients with respiratory complications
  • Prevention of disease progression to invasive mechanical ventilation and ECMO

The research center focuses on evaluating innovative treatments aimed at preventing progression to invasive mechanical ventilation and reducing mortality in hospitalized patients with viral pneumonia. Their clinical trial portfolio emphasizes the assessment of targeted biological agents as add-on therapies to standard of care, with particular attention to patient outcomes including survival and respiratory function stabilization in acute respiratory failure settings.

Site Overview

assignment
3
connected trials
corporate_fare
3
sponsors
science
3
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
3
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 634 other sites in Czechia

description
Trial volume
3
Outperforms 59% of sites
public
Therapeutic diversity
1areas
Outperforms 5% of sites
groups
Sponsor diversity
3sponsors
Outperforms 68% of sites

Therapeutic Area Benchmark — Czechia

Select a therapeutic area to compare against other sites in Czechia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Czechia

Market Share

Country: Czechia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Nemocnice Rudolfa a Stefanie Benešov, a. s.

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety of Maridebart Cafraglutide in Adults with Moderate to Severe Obstructive Sleep Apnea and Overweight or Obesity Receiving Positive Airway Pressure TherapyAmgen Inc.Phase IIIRecruitingFeb 2026

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-Pyran-4-Yl)-2-((S)-3-(3-(4-Fluoro-1-Methyl-1H-Indazol-5-Yl)-2-Oxo-2,3-Dihydro-1H-Imidazol-1-Yl)-2-(4-Fluoro-3,5-Dimethylphenyl)-4-Methyl-4,5,6,7-Tetrahydro-2H-Pyrazolo[4,3-C]Pyridine-5-Carbonyl)-1H-Indol-1-Yl)-2-Methylcyclopropyl)-5-Oxo-1,2,4-Oxadiazol-4-Ide Hemicalcium1Unknown2025-01-292025-01-29

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.